TELA Bio, Inc.
TELA Bio, Inc. (Nasdaq: TELA) is a commercial-stage medical technology company that develops and sells soft-tissue reconstruction products for surgeons and healthcare providers. Its main product portfolios are OviTex Reinforced Tissue Matrix, used in hernia repair and abdominal wall reconstruction, and OviTex PRS… From the company’s description.
Over the twelve months to Jun 30, 2026, TELA Bio, Inc. reported revenue of $79.91M, up 6.1% from a year earlier, and a net loss of $41.18M. Its operating margin was −42.6%, and operations used $31.14M in cash. In fiscal 2025, it reported revenue of $80.28M, up 15.8% from fiscal 2024, and a net loss of $38.83M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What TELA Bio, Inc. does
In the company’s own words
TELA Bio, Inc. (Nasdaq: TELA) is a commercial-stage medical technology company that develops and sells soft-tissue reconstruction products for surgeons and healthcare providers. Its main product portfolios are OviTex Reinforced Tissue Matrix, used in hernia repair and abdominal wall reconstruction, and OviTex PRS Reinforced Tissue Matrix, designed for plastic and reconstructive surgery. Both combine layers of biologic material derived from ovine rumen with interwoven polymer fibers; configurations use permanent or resorbable polymers. OviTex products address ventral, inguinal and hiatal hernia procedures, including laparoscopic and robotic-assisted repairs, while OviTex PRS is used to reinforce soft tissue in reconstructive procedures. The company primarily sells through a direct sales force in the United States, with a smaller presence in the United Kingdom and European Union, as well as independent contractors and distributors. Its products are manufactured by Aroa Biosurgery under an exclusive supply arrangement. Revenue was $80.3 million for fiscal 2025.
Company details
- Sector
- Health Care
- Industry (SIC)
- Surgical & Medical Instruments
- Headquarters
- MALVERN, PA
- Fiscal year end
- December
- CIK
- 1561921
- SIC
- 3841
Financial performance, year by year
Fiscal 2019–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns TELA Bio, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · TELA Bio, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do TELA Bio, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of TELA Bio, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in TELA Bio, Inc.'s last four quarterly filings that the numbers alone won't show?”